Loading company
$174.10-5.1%Nov 12 close
Figures through September 30, 2026, from the 10-Q filed October 29, 2026
Past performance
- 1W
- -9.0%
- 1M
- -3.7%
- 3M
- -3.3%
- 6M
- -9.6%
- 1Y
- +43.2%
- 5Y
- +63.6%
Just reported
From Davita's results release of October 29, 2026; its quarterly report has since been filed.
Actual
$3.58B
+4.6% y/y
+0.7% q/q
Guided
—
No guide given
Actual
$3.40
+67% y/y
-15% q/q
Guided
—
No guide given
Actual
$499.3M
-1.3% y/y
-14% q/q
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Built from Davita Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
$174.10-5.1%Nov 12 close
Figures through September 30, 2026, from the 10-Q filed October 29, 2026
The themes Davita is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
THCTenet Healthcare Corp.$22.8BA+
EHCEncompass Health Corporation$13.8BA+
ENSGEnsign Group, Inc.$10.9BA
PACSPACS Group, Inc.$7.6BA
CONConcentra Group Holdings Parent, Inc.$5.4BARose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher CorporationOct 21, 2026CBGraded C, now B
MCKMckesson CorporationNov 4, 2026BAGraded B, now A
CVSCVS Health CorpNov 4, 2026BAGraded B, now A
EWEdwards Lifesciences CorporationNov 4, 2026BAGraded B, now A
BIIBBiogen Inc.Oct 28, 2026BAGraded B, now AGrade C
The band under the price shows the grade on each date, built only from filings that were public by then.
Showing 2 of 32 quarters of Davita Inc.’s grade history. The other 30 go back to February 2019.
